Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386556 | 0.85 | — | — | |
| SCHEMBL8922266 | 0.79 | TDP1 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL22652 | 0.75 | — | — | |
| SCHEMBL497349 | 0.75 | P2RY14 (0.34) | ALDH1A1TDP1 | |
| Water SCHEMBL6908198 | 0.75 | LPAR3 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL5485766 | 0.73 | — | — | |
| SCHEMBL7216239 | 0.73 | LPAR3 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL6653137 | 0.73 | LPAR3 (0.40) | ALDH1A1TDP1 | |
| SCHEMBL6998234 | 0.73 | LPAR3 (0.40) | ALDH1A1TDP1 | |
| Water SCHEMBL11512537 | 0.73 | LPAR3 (0.40) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481743-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUND (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2433946-B1 | LPA receptor agonists and antagonists and methods of use | UNIV TENNESSEE RES FOUNDATION (US) | 2016-04-20 | — | — | EP | disclosed |
| EP-2767541-A1 | LPA receptor agonists and antagonists | Rxbio, Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2262371-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2481743-A1 | LPA receptor agonists and antagonists and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | MILLER DUANE D (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2433946-A1 | LPA receptor agonists and antagonists and methods of use | University of Tennessee Research Foundation (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | RXBIO INC. | 2012-01-12 | — | — | US | disclosed |
| EP-1678096-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES FOUNDATION (US) | 2012-01-04 | — | — | EP | disclosed |
| US-7947665-B2 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2011-05-24 | — | — | US | disclosed |
| WO-2010051053-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS | RXBIO, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | MILLER DUANE D | 2008-04-17 | — | — | US | disclosed |
| US-7217704-B2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1678096-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1678096-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-07-12 | — | — | EP | disclosed |
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-01-12 | — | — | US | disclosed |
| WO-2005032494-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-14 | — | — | WO | disclosed |
| US-5644048-A | Process for preparing phosphorothioate oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| WO-1994019363-A1 | PROCESS FOR PREPARING PHOSPHOROTHIOATE OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1994-09-01 | — | — | WO | disclosed |
| US-5210264-A | S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester | ISIS PHARMACEUTICALS, INC. (US) | 1993-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009507-A1 | Thio-phosphoric and -phosphorous acid derivatives; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR6, LPAR2 | ALDH1A1 1415/4885TDP1 1152/4885 |
| US-20120010424-A1 | LPA Receptor Agonists and Antagonists | LPAR1, LPAR2, LPAR4 | ALDH1A1 1405/4885TDP1 2073/4885 |
| US-20120135967-A1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | LPAR1, LPAR2, LPAR4 | ALDH1A1 664/4885TDP1 2456/4885 |
| US-20080090783-A1 | lysophosphatidic acid receptor modulator; thiophosphoric acid O-[7-(4-octyl-phenyl)-heptyl] ester; treating cancer, wounds, skin disorders and apoptosis; preserving or restoring function in a cell, tissue or organ; culturing cells; preserving organ or tissue function; and enhancing cell proliferation | LPAR1, LPAR4, LPAR2 | ALDH1A1 1703/4885TDP1 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.